In 2021, the global gene therapy market was estimated to be worth $1.55 billion USD. The market is expected to increase from US$ 1.85 billion in 2022 to US$ 10.1 billion by 2032, at an 18.5%… Read More
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that its bispecific antibody Talvey (talquetamab-tgvs) received US Food and Drug Administration (FDA) approval as a fi… Read More
In a world where health is paramount, the pharmaceutical industry stands as a formidable pillar, relentlessly pursuing scientific breakthroughs and life-saving innovations. With each passing… Read More
Overview
When other treatments for multiple myeloma have failed, CAR T-cell therapy is a sort of immunotherapy that is employed. While the rates of remission and survival have increased, the… Read More
CHICAGO — More than 70% of patients with heavily pretreated multiple myeloma had responses to the novel bispecific antibody talquetamab plus subcutaneous daratumumab (Darzalex Fasp… Read More
Bharat Book Bureau Provides the Trending Market Research Report on “Global CAR T Cell Therapy Market & Clinical Trials Insight 2028” under the Life Sciences Market Research R… Read More
The October inflation quantities came out previous week, and sparked reliable gains in the marketplaces. Investors have been buoyed by much better-than-anticipated cost knowledge whe… Read More
The latest industry analysis on Gene Therapy Market provides sales outlook in 20+ countries, across key categories Product, Application, Sales Channel. Insights on Gene Therapy Market driver… Read More
T-cell transfer therapy is a class of immunotherapy used to treat various cancers.
T-cell transfer therapy consists of two main subclasses: tumor-infiltrating lymphocytes (TIL) therapy an… Read More
Bristol (BMY) earned $1.93 per share. Analysts had projected slightly lower revenues of $11.4 billion for the quarter and $1.77 per share profits. However, when accounting for fluctuations i… Read More
Developed in partnership with Legend Biotech Corp of China, Johnson & Johnson’s cell therapy Carvykti (formerly known as cilta-cel) received approval from the US Food and Drug Admi… Read More
Each year in the first quarter, the HCPCS Level II code set is refreshed with several new, revised, and deleted codes. CMS explains Level II of the HCPCS as a standardized coding system that… Read More
Viral Vectors and Plasmid DNA Manufacturing Market Research Report: Information by Vector Type (Plasmid DNA, Viral Vector, Non-viral Vector), by Disease Type(Cancer, Genetic Disorder, and In… Read More
CAR or Chimeric Antigen Receptor T-cell therapy is a type of cancer treatment in which a patient’s T lymphocytes or T cells are chemically reengineered in a laboratory so that they wil… Read More
For Immediate Release: March 27, 2021 The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma… Read More